Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

NCT03612791 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Cervical Cancer

Interventions

DRUG: Atezolizumab
RADIATION: Radiotherapy
DRUG: Cisplatin

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris